首页> 美国卫生研究院文献>Toxicological Research >The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
【2h】

The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells

机译:选择性雌激素受体调节剂(SERMs)对他莫昔芬耐药乳腺癌细胞的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to estrogen receptors (ER) and can modulate its transcriptional capabilities in different ways in diverse estrogen target tissues. Tamoxifen, the prototypical SERM, is extensively used for targeted therapy of ER positive breast cancers. Unfortunately, the use of tamoxifen is associated with acquired resistance and some undesirable side effects. This study investigated the availability of the conventional SERMs on the TAM-resistance breast cancer cells. SERMs showed more effectiveness in MCF-7 cells than tamoxifen resistant cells, except toremifene and ospemifene. Especially, toremifene was more efficacious in tamoxifen resistant cells than MCF-7. Ospemifene had similar cytotoxic activity on the two types of breast cancers. The other SERMs used in this experiment didn’t inhibit efficiently the proliferation of tamoxifen resistant cells. These results support the possibility to usage of toremifene on tamoxifen resistant cancer. The effectiveness by toremifene on tamoxifen resistant cells might be different pathways from the apoptosis and the autophagy. Further study should be needed to elucidate the underlying mechanism of effect of toremifene on tamoxifen resistant cancer.
机译:选择性雌激素受体调节剂(SERM)是与雌激素受体(ER)结合的合成分子,可以在多种雌激素靶组织中以不同方式调节其转录能力。他莫昔芬是SERM的原型,已广泛用于ER阳性乳腺癌的靶向治疗。不幸的是,他莫昔芬的使用与获得的耐药性和一些不良副作用有关。这项研究调查了常规SERMs在TAM抗性乳腺癌细胞上的可用性。 SERMs在MCF-7细胞中显示出比他莫昔芬抗性细胞更多的功效,除了托瑞米芬和奥司米芬外。特别是,托瑞米芬在他莫昔芬耐药细胞中比MCF-7更有效。奥司米芬对两种类型的乳腺癌具有相似的细胞毒活性。该实验中使用的其他SERM不能有效抑制他莫昔芬耐药细胞的增殖。这些结果支持在他莫昔芬耐药的癌症中使用托瑞米芬的可能性。托瑞米芬对他莫昔芬耐药细胞的有效性可能与凋亡和自噬途径不同。需要进一步研究阐明托瑞米芬对他莫昔芬耐药性癌症的潜在作用机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号